scholarly journals Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy

2010 ◽  
Vol 51 (10) ◽  
pp. 3055-3061 ◽  
Author(s):  
Stephen J. Nicholls ◽  
W. H. Wilson Tang ◽  
Heather Scoffone ◽  
Danielle M. Brennan ◽  
Jaana Hartiala ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Statin Therapy ◽  
Lipoprotein A

scholarly journals Adherence to statin therapy in patients with high and very high cardiovascular risk in real clinical practice

2020 ◽  
Vol 11 (1) ◽  
pp. 38-48
Author(s):  
V. I. Podzolkov ◽  
A. E. Bragina ◽  
L. V. Vasil’eva ◽  
Yu. P. Grintsevich ◽  
Yu. N. Rodionova
Keyword(s):  
Clinical Practice ◽  
Cardiovascular Risk ◽  
Statin Therapy ◽  
Charlson Comorbidity Index ◽  
High Cardiovascular Risk ◽  
Positive Correlation ◽  
Comorbidity Index ◽  
Very High ◽  
Real Clinical Practice

Despite the proven efficacy of lipid-lowering therapy, adherence to long-term statin therapy in patients with cardiovascular disease remains low.Aim. To study adherence to long-term statin therapy and factors associated with adherence in patients with high and very high cardiovascular risk (CVR) in real clinical practice.Materials and methods. The single-center cohort study included 53 patients (mean age 68.1 ± 10.2 years) with high or very high CVR on the SCORE scale and have been taking statins for at least 3 months prior to inclusion in the study. The level of low-density lipoprotein cholesterol (LDL-C), cognitive impairment (MoCA test), anxiety and depression (HADS scale), presence of senile asthenia (FRAIL scale), M. Charlson comorbidity index were assessed. Adherence to statin therapy was assessed using the original questionnaire. The correlation between patient adherence and ordinal variables for the scores of the studied scales was studied.Results. Completely adherent to statin therapy were only 12 (22%) patients, 14 (26%) were insufficiently adherent, 27 (51%) were non-adherent. The target level of LDL-С was achieved in 13 (25%) patients. 38 (72%) patients showed a decrease in cognitive functions; a positive correlation was found between adherence and the MoCA test (r = 0.44, p = 0.04). Clinical and subclinical depression and anxiety were noted in 12 (23%) and 14 (26%) patients, respectively. A statistically significant negative correlation was found between adherence and depression (r = –0.32; p = 0.04) and a positive correlation between adherence and anxiety (r = 0.44; p = 0.04). There was no statistically significant correlation between adherence and the FRAIL fragility scale, as well as the M. Charlson comorbidity index.Conclusions. Depression and cognitive decline are associated with decreased adherence to statin therapy.

Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN

2017 ◽  
Vol 263 ◽  
pp. 137-144 ◽  
Author(s):  
Rishi Puri ◽  
Christie M. Ballantyne ◽  
Ron C. Hoogeveen ◽  
Mingyuan Shao ◽  
Philip Barter ◽  
...  
Keyword(s):  
Statin Therapy ◽  
High Intensity ◽  
Lipoprotein A ◽  
Coronary Atheroma

Long-Term Exposure to Elevated Lipoprotein(A) Levels Influences Human Longevity

2019 ◽  
Author(s):  
Benoit Arsenault ◽  
William Pelletier ◽  
Yannick Kaiser ◽  
Nicolas Perrot ◽  
Christian Couture ◽  
...  
Keyword(s):  
Human Longevity ◽  
Lipoprotein A

Lipoprotein (a) and Cardiovascular Risk: The Show Must go on

2017 ◽  
Vol 24 (10) ◽  
pp. 989-1006 ◽  
Author(s):  
Niki Katsiki ◽  
Khalid Al-Rasadi ◽  
Dimitri P. Mikhailidis
Keyword(s):  
Cardiovascular Risk ◽  
Lipoprotein A
Sign in / Sign up

Export Citation Format

Share Document